The trillions of microbes that call us home –the human microbiome – perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases.

For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious diseases develop. This language is based on a system of signals that our resident microbes use to successfully colonize us, such as byproducts of bacterial metabolism and factors that bacteria use to adapt to human niches. Recent discoveries have shown that most of these signals do not lead to disease, rather, they promote our long-term survival.

Vedanta is developing a novel class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. Vedanta was co-founded by PureTech Health and a group of world renowned experts in immunology and microbiology

Biomedical Advanced Research and Development Authority (BARDA)

CARB-X

Hambro Perks Ltd.

SV Investment Corp

Shinhan Capital

Shinhan Private Equity

FC Capital

Partners Investment

QUAD Investment Management

Health for Life Capital fund

Skyviews Life Science

SymBiosis LLC

Verition Fund Management

Rock Springs Capital

Shumway Capital

JSR Corp

Magnetar Capital

PureTech Health

Revelation Partners

Korea Investment Holdings

Korea Investment Partners

AMR Action Fund

Atlantic Neptune

Fiscus Ventures

Peak 6

Pfizer Breakthrough Growth Initiative

Vedanta Biosciences, Inc.

Colorcon Ventures, the corporate venture fund of Colorcon® Inc., has invested in Vedanta Biosciences, Inc., a clinical stage life sciences company that designs and manufactures proprietary, orally delivered bacterial therapies.

Ali Rajabi-Siahboomi, Vice President and Chief Innovation Officer at Colorcon, said, “Vedanta Biosciences is aligned with Colorcon Ventures’ interest in emerging classes of drugs for oral administration. The company’s unique approach within microbial therapeutics has the potential to offer safer and more efficacious treatments for a number of indications. Vedanta has also revolutionized the manufacturing of defined bacterial consortia at scale, which adds significant value to the sector. We look forward to supporting Vedanta Biosciences as they realize the full potential of their platform technology.”

Press Release ➡️https://hubs.ly/Q02lRXmx0

Alveolus develops therapeutics for lung diseases such as live biotherapeutics for various pulmonary conditions.

Alveolus

LISCure Biosciences is a competitor of Vedanta Biosciences in the biotechnology sector.

LISCure Biosciences

x-chemrx.com is a potential or emerging competitor with high similarity score to vedantabio.com.

x-chemrx.com

Vedanta Biosciences is a developer of immunotherapies designed to treat immune-mediated and infectious diseases. It includes a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally defined bacterial consortia in powder form to help physicians have access to live bacteria drugs to treat autoimmune and inflammatory diseases easily.

Vedanta Biosciences

industry_trends_dossier

news_impact_assignment_basic

key_people

company_dossier

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

network

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

events

strategic_challenges

network_mapping

industry_trends

transactions_dossier

strategic_challenges_dossier

financial_statements

network_onboarding

company_summary

signals

regulatory_analysis

industry_analysis

swot_analysis

swot_dossier

competition_analysis

financial_legal_advisories

merger_acquisitions

news_advanced

news_impact_assignment_advanced

news_processing_advanced

peers

news_basic

valuation

customer_profile

industry trends dossier	dataroom
company dossier	dataroom
network	dataroom
network mapping	dataroom
transactions dossier	dataroom
network onboarding	dataroom	Mar 8, 2024 1:41 AM	69d148a2
news impact assignment basic	general	Mar 8, 2024 1:41 AM	a346781e
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 1:41 AM	34baa45b
company summary	general
signals	general	Mar 8, 2024 1:41 AM	21a0409c
news advanced	general
news impact assignment advanced	general
news processing advanced	general
peers	general	Mar 8, 2024 1:41 AM	9a6e6fb0
news basic	general	Mar 8, 2024 1:41 AM	2b63c483
events	markdown
bundesanzeiger	filings
financial statements	filings
regulatory analysis	company_analysis
industry analysis	company_analysis
swot analysis	company_analysis
competition analysis	company_analysis
financial legal advisories	company_analysis
merger acquisitions	company_analysis
customer profile	customers

COM:VEDANTABIO

Vedanta Biosciences